Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Hydroquinone

Also known as: HQ, 1,4-dihydroxybenzene

Hydroquinone is a medicine applied to the skin to reduce the production of melanin, its brown pigment. It is used for selected pigmentation conditions, particularly melasma, either alone or in combination creams under clinical supervision.

In plain English — Hydroquinone reduces the production of the pigment that gives skin its colour. It can help lighten some dark patches, including melasma, when the diagnosis and medicine are appropriate. Treatment needs clinical supervision because irritation and unwanted colour changes can occur.

Evidence status

Moderate

Established melasma treatment; formulation-specific evidence. Trials support hydroquinone-containing treatment for melasma, including greater short-term efficacy of one fixed triple combination than hydroquinone alone. Evidence for other pigment disorders, long-term outcomes and rare harms is less secure; the diagnosis and exact preparation matter.

What hydroquinone is, and the types available#

Hydroquinone is a topical depigmenting medicine.[1, 2] Preparations include single-active creams and combinations with a retinoid and a corticosteroid. These have different benefit and safety profiles: evidence for a named combination belongs to that combination. Monobenzone is a separate depigmenting agent, rather than another name for the same medicine.[1, 3]

The subject here is the medicine. Melasma, post-inflammatory hyperpigmentation and the hyperpigmentation differential cover the conditions for which a client may seek advice.

Use of hydroquinone in aesthetic practice#

The British Association of Dermatologists describes hydroquinone-containing melasma treatment as prescribed care requiring medical supervision. For a non-prescribing skincare professional, the role is to recognise when assessment would help and support the agreed care plan, rather than initiate or alter the medicine.[2]

Great Britain: the applicable cosmetics regulation prohibits hydroquinone skin-lightening cosmetics. Its narrow artificial-nail exception does not provide a route for facial products.[10, 11, 13] Northern Ireland: the separate EU-aligned cosmetics framework has the same relevant restriction. These are cosmetic-market rules, not a ban on all medicinal use.[12, 14]

Medicine supply follows the exact product’s classification. Prescription-only packs require a valid prescription; pharmacy medicines follow the pharmacy supply route. MHRA’s 2023 table recorded Symba Skin Toner 2% as a pharmacy medicine. That historical record is not confirmation of current availability: the dispensing pharmacy must establish the current product and lawful supply route.[15, 16]

Contraindications and cautions#

Pregnancy and breastfeeding. BAD advises avoiding hydroquinone during pregnancy. Lactation safety is not established in the clinical reference; individual prescribing advice is needed. Combination creams require consideration of every active ingredient, including any retinoid.[1, 2]

Allergy and current reactions. Known allergy to hydroquinone or an excipient excludes that preparation. Preservatives such as metabisulphite may be relevant. Existing skin reactions need assessment before additional active treatment.[1, 2]

Clinical uses and the evidence behind them#

Melasma

An eight-week investigator-blinded trial in East/South-East Asian adults with moderate-to-severe facial melasma compared fixed fluocinolone 0.01%/hydroquinone 4%/tretinoin 0.05% with hydroquinone 4%. None or mild melasma at the endpoint was recorded in 77/120 participants (64.2%) receiving the triple cream and 48/122 (39.4%) receiving hydroquinone alone. Galderma funded the study, paid investigators and employed two authors. The finding supports the tested combination’s short-term advantage; its tolerability trade-off appears below.[3]

A broader review included 45 studies and 2,359 participants in its efficacy analysis. Hydroquinone monotherapy improved severity from baseline (standardised mean difference −1.3; 95% CI −1.6 to −1.0). Several non-hydroquinone agents also improved outcomes, and the authors regarded them as alternatives. This synthesis pooled within-group changes across heterogeneous studies, not a single randomised ranking of all ingredients. No formal GRADE rating was reported.[4]

Post-inflammatory hyperpigmentation

A four-month facial post-acne pigmentation pilot compared pharmacist-compounded hydroquinone 4%/ascorbic acid 3% with 5% cysteamine. Eligibility was ages 14–40 after inflammatory acne had resolved; 28 completed. Both groups improved without a significant difference between them. The trial had public university funding and a cysteamine-company shareholder among its authors. It provides preliminary formulation-specific evidence, not proof of equivalence or an isolated hydroquinone effect.[5]i

The underlying diagnosis remains important: managing pigment left by inflammation and managing continuing inflammatory disease are related but distinct tasks.[1, 2, 4]i

Selecting hydroquinone treatment#

Selection is a clinical decision based on the pigment disorder, previous response, skin tolerance and the complete medicine. Evidence for epidermal pigmentation is more relevant than an expectation of clearing pigment held deeper in the skin. The product’s prescribing information and individual treatment plan govern use; trial concentrations and durations reported here are descriptions, not a protocol.[1, 2, 4]i

Light protection remains part of melasma care. The sunscreen and SPF entry covers that separate choice, while azelaic acid and other pigmentation entries describe alternative ingredients with their own evidence.[1, 2, 4]i

Adverse effects and their management#

Irritation

Undue redness, scaling, itching or weeping calls for discontinuing the preparation and seeking clinical advice. The response is assessed in the context of the whole cream and other exposures; adding further irritating treatment can obscure the cause. Any prescription change belongs with the treating clinician.[1, 2]i

In Chan’s trial, related adverse events occurred in 63/129 participants (48.8%) on triple cream and 18/131 (13.7%) on hydroquinone alone. Most were mild and none severe. These are safety-population denominators, distinct from the efficacy counts above, and should not be treated as universal reaction rates.[3]

Unwanted colour changes

Exogenous ochronosis is a recognised adverse effect associated with hydroquinone exposure. A systematic review assembled 126 affected people across 56 reports; characteristic findings were blue-black or grey-blue, lace-like facial pigmentation. Median reported use was five years, although some cases followed shorter exposure. This case-selected literature cannot estimate how often the complication occurs among all users or establish a risk-free duration.[6]i Unusual new darkening calls for prompt medical assessment, rather than interpreting it as a need for stronger lightening.[2, 6]i

Referral and scope boundaries#

Diagnostic uncertainty, a changing mole or a changing patch requires medical assessment before it is treated as routine pigmentation. A prescriber or dermatology service is also the appropriate route for assessing suitability for hydroquinone and reviewing an unsatisfactory response.[2, 6]i

When an adverse effect is suspected, the preparation name, ingredients, source, exposure history and evolution of the change are useful clinical information. The reaction-specific concerns are described above; the aesthetic role is to facilitate assessment rather than substitute a different depigmenting medicine. This is a scope synthesis from the clinical guidance and adverse-effect evidence.[2, 6]i

Mechanism of action#

Hydroquinone reduces new melanin formation, including effects on tyrosinase, an enzyme involved in pigment synthesis. Its main clinical target is epidermal pigment production. This differs from physically removing pigment already deposited deeper in the skin.[1]

In combination creams, the retinoid and corticosteroid contribute additional actions. The clinical result therefore reflects the tested preparation rather than the hydroquinone molecule in isolation.[1, 3]

Commonly misstated claims#

Response ratios and pigment outcomes

Claim heard:“Triple cream removes 58% more pigment”

Literature finding:The Cochrane comparison reported a response risk ratio of 1.58 (95% CI 1.26–1.97), not a percentage of pigment removed. Its search ended in May 2010, and the review described generally poor-quality, heterogeneous evidence.[8]i

Supported statement: Triple combination improved the chance of the measured response compared with hydroquinone alone in that evidence base.[8]i

Formulation-specific absorption

Claim heard:“The skin always absorbs 45% of hydroquinone”

Literature finding:A 1998 human experiment reported 45.3 ±11.2% bioavailability after a 24-hour exposure to one radiolabelled 2% cream. Separate excised-human-skin experiments were also performed. The accessible abstract omits volunteer number, body site and the meaning of the dispersion figure.[7]i

Supported statement: Systemic uptake was demonstrated under particular experimental conditions; the number is not an absorption constant for every preparation or pattern of use.[7]i

Carcinogenicity assessment and exposure route

Claim heard:“IARC established that prescribed facial hydroquinone causes cancer”

Literature finding:IARC’s 1999 evaluation found inadequate human evidence and limited animal evidence, assigning Group 3. The animal evidence included oral-exposure studies; that is a different question from risk during supervised topical facial use.[9]i

Supported statement: This historical hazard assessment neither demonstrated human topical carcinogenicity nor certified the medicine as risk-free.[9]i

Areas of remaining uncertainty#

  • Persistence of benefit: melasma commonly recurs after treatment ends; expectations therefore need to distinguish improvement from durable remission.[2, 3]i
  • Evidence outside melasma: the post-acne pilot had a small completer group, inconsistent recruitment totals and no subsequent follow-up; its result should remain preliminary when discussing other pigmentation conditions.[5]i
  • Comparison between alternatives: pooled before/after improvements depend on different preparations and study populations; selection therefore remains individual rather than based on a numerical ingredient league table.[4]

Frequently asked questions#

Which information should accompany a client asking about hydroquinone?

The diagnosis, exact preparation, previous response and any reaction are central. The prescribing or dispensing clinician can then assess the medicine in context.[1, 2, 4]i

Where are the differences between pigment disorders explained?

The hyperpigmentation entry is the differential page, with separate entries for melasma and post-inflammatory hyperpigmentation. The subject here is the medicine used for selected cases.

Can a cosmetic routine accompany prescribed treatment?

Supportive care can form part of the agreed plan. Light protection is relevant to melasma, while tolerance and the medicine’s instructions govern compatibility; product changes should be coordinated with its clinical supervision.[2]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Ngan V; updated by Coulson I. Hydroquinone. DermNet. September 2021.Tier 4Supports: Clinical identity, preparations, epidermal-pigment action, allergy, intolerance and distinction from monobenzone. Full clinical text retrieved.Funding / interest: No article-specific funding or conflict statement located on the retrieved educational page.
  2. British Association of Dermatologists. Melasma. Patient information leaflet. Updated June 2024.Tier 4Supports: UK clinical consensus on supervised medicine use, pregnancy avoidance, light protection, recurrence and assessment of changing lesions.Funding / interest: Professional-association patient leaflet expressly described as consensus; no commercial sponsor stated.
  3. Chan R, Park KC, Lee MH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 2008;159(3):697–703. doi:10.1111/j.1365-2133.2008.08717.x. PMID:18616780.Tier 2Supports: Eight-week facial melasma comparison in East/South-East Asian adults; primary efficacy and adverse-event denominators differ. Publisher abstract and disclosure retrieved.Funding / interest: Galderma funded the trial and paid investigators; Kerrouche and Thomas were company employees.
  4. Chang YF, Lee TL, Oyerinde O, et al. Efficacy and safety of topical agents in the treatment of melasma: What's evidence? A systematic review and meta-analysis. J Cosmet Dermatol. 2023;22(4):1168–1176. doi:10.1111/jocd.15566. PMID:36566490.Tier 1Supports: Pooled before/after severity changes, differing efficacy/safety datasets, heterogeneity and authors' favourable view of non-hydroquinone alternatives. Full text retrieved.Funding / interest: Conflict statement says Not applicable; no separate funding statement located in the retrieved full text. Commercial independence is not inferred.
  5. Ahmadi K, Miri A, Bizaval Z, et al. Assessing the effectiveness of stabilized cysteamine 5% cream compared to hydroquinone 4%/ascorbic acid 3% combination cream in treating acne-induced post-inflammatory hyperpigmentation: a randomized, controlled study. J Clin Aesthet Dermatol. 2024;17(4):37–41. PMID:38638185.Tier 2Supports: Four-month facial post-acne PIH pilot with 28 completers; two active formulations improved. Recruitment totals differ internally; no equivalence design or post-treatment follow-up. Full text retrieved.Funding / interest: Shiraz University of Medical Sciences grant. Kasraee was affiliated with and a shareholder of Scientis SA, the cysteamine supplier; other authors declared no relevant conflicts.
  6. Ishack S, Lipner SR. Exogenous ochronosis associated with hydroquinone: a systematic review. Int J Dermatol. 2022;61(6):675–684. doi:10.1111/ijd.15878. PMID:34486734.Tier 1Supports: Review of 56 case reports/series containing 126 affected people; presentation and reported exposures, not incidence in treated users. Indexed abstract retrieved.Funding / interest: Funding and conflict declarations were unavailable in the retrieved abstract.
  7. Wester RC, Melendres J, Hui X, et al. Human in vivo and in vitro hydroquinone topical bioavailability, metabolism, and disposition. J Toxicol Environ Health A. 1998;54(4):301–317. doi:10.1080/009841098158863. PMID:9638901.Tier 3Supports: One radiolabelled 2% cream under 24-hour human experimental exposure; separate excised-human-skin arm. Abstract does not report volunteer number or body site.Funding / interest: Funding and conflicts were unavailable in the retrieved indexed abstract.
  8. Cochrane. Interventions for melasma. Cochrane Database Syst Rev. CD003583. doi:10.1002/14651858.CD003583.pub2. Website citation 2022; searches ended May 2010.Tier 1Supports: Twenty trials across treatments; triple-combination versus hydroquinone response ratio and poor-quality/heterogeneous evidence caveat. Complete summary and abstract retrieved.Funding / interest: Review funding and conflict details were not supplied in the accessed summary.
  9. IARC. Hydroquinone. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 71. 1999.Tier 4Supports: Historical hazard evaluation: inadequate human evidence, limited animal evidence, Group 3. Not a contemporary estimate of cancer risk from prescribed facial use.Funding / interest: IARC institutional expert evaluation; no product-manufacturer sponsorship asserted.
  10. Regulation (EC) No 1223/2009 as applicable in Great Britain. Annex II, entry 1339. Accessed 16 September 2026.Tier 1Supports: Hydroquinone prohibition with the specified annex III exception; official XML row retrieved.Funding / interest: Primary legislation; no commercial study sponsorship.
  11. Regulation (EC) No 1223/2009 as applicable in Great Britain. Annex III, entry 14. Accessed 16 September 2026.Tier 1Supports: Restricted professional artificial-nail exception, not a skin-lightening cosmetic permission; official XML row retrieved.Funding / interest: Primary legislation; no commercial study sponsorship.
  12. European Union. Regulation (EC) No 1223/2009, consolidated 1 May 2026. Annex II entry 1339 and annex III entry 14.Tier 1Supports: EU cosmetic restriction applicable through Northern Ireland's separate framework, including artificial-nail exception. Relevant rows retrieved.Funding / interest: Primary EU legal text; no commercial study sponsorship.
  13. OPSS. Regulation 1223/2009 and the Cosmetic Products Enforcement Regulations 2013: Great Britain. Updated 29 June 2026.Tier 1Supports: Great Britain territorial scope and distinction between cosmetic and medicinal products.Funding / interest: UK government statutory guidance.
  14. OPSS. Regulation 1223/2009 and the Cosmetic Products Enforcement Regulations 2013: Northern Ireland. Updated 29 June 2026.Tier 1Supports: Northern Ireland's EU-aligned cosmetics framework under the Windsor Framework; not inferred from GB guidance.Funding / interest: UK government statutory guidance specific to Northern Ireland.
  15. MHRA. FOI 23-917, product-table attachment. 2023. Page 221, PL 48259/0052.Tier 1Supports: Historical Symba Skin Toner 2% row marked P. PDF downloaded, relevant page text-extracted and rendered; does not establish 2026 availability.Funding / interest: MHRA administrative disclosure, not company advertising or an efficacy study.
  16. MHRA. Medicines: reclassify your product. Updated 3 September 2026.Tier 1Supports: Medicine-pack classification, prescription-only and pharmacy supply boundaries.Funding / interest: UK medicines-regulator guidance.